Dr.NateNeph — wow. This community is amazing.

Slightly tangential to Patient preference weekly but JakeBK_lifts reminded me — what is the latest on the oral formulations?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Thanks for sharing this, JakeBK_lifts. A few questions about your Patient preference experience:

1. What dose worked best for you?
2. How long before you noticed appetite suppression kicking in?
3. Did your endo have any specific recommendations about Patient prefere?

I am in a similar boat and trying to learn from others' experiences before my next appointment.

OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on Patient preference weekly.

To answer SteveThurs: yes, I am on compounded sema from a 503B pharmacy.

Quick update: things are still going well. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏

Relevant to Patient preference weekly — here is my latest bloodwork comparison:

Key improvements: A1C 7.6% → 5.5%, triglycerides 221 → 91 mg/dL, hsCRP 8.0 → 0.9 mg/L. All on tirzepatide for 13 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.